{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:39:35Z","timestamp":1791419975611,"version":"4.3.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,9]],"date-time":"2015-05-09T00:00:00Z","timestamp":1431129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12891-015-0569-3","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T12:10:04Z","timestamp":1431087004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Der-Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wei","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,9]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1073\/pnas.91.12.5710","volume":"91","author":"MA Smith","year":"1994","unstructured":"Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91:5710\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1172\/JCI3042","volume":"104","author":"MM Anderson","year":"1999","unstructured":"Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103\u201313.","journal-title":"J Clin Invest"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2474-11-83","volume":"11","author":"R Vytasek","year":"2010","unstructured":"Vytasek R, Sedova L, Vilim V. Increased concentration of two different advanced glycation end-products detected by enzyme immuno- assays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:83.","journal-title":"BMC Musculoskelet Disord"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-3083.2007.02001.x","volume":"66","author":"J Li","year":"2007","unstructured":"Li J, Hou F, Guo Z, Shan Y, Zang X, Liu Z. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand J Immunol. 2007;66:555\u201362.","journal-title":"Scand J Immunol"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/rheumatology\/kem215","volume":"46","author":"K Leeuw de","year":"2007","unstructured":"de Leeuw K, Graaff R, de Vries R, Dullaart RP, Smit AJ, Kallenberg CG, et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:1551\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/rheumatology\/ken302","volume":"47","author":"HL Nienhuis","year":"2008","unstructured":"Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford). 2008;47:1554\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2008.04.019","volume":"7","author":"BT Kurien","year":"2008","unstructured":"Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev. 2008;7:567\u201373.","journal-title":"Autoimmun Rev"},{"key":"569_CR8","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","volume":"267","author":"M Neeper","year":"1992","unstructured":"Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998\u20135004.","journal-title":"J Biol Chem"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","volume":"1498","author":"AM Schmidt","year":"2000","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99\u2013111.","journal-title":"Biochim Biophys Acta"},{"key":"569_CR10","first-page":"257","volume":"51","author":"JA Mosquera","year":"2010","unstructured":"Mosquera JA. Role of the receptor for advanced glycation end products (RAGE) in inflammation. Invest Clin. 2010;51:257\u201368.","journal-title":"Invest Clin"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2741\/3315","volume":"14","author":"L Lin","year":"2009","unstructured":"Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci. 2009;14:1403\u201313.","journal-title":"Front Biosci"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0961203312444495","volume":"21","author":"HA Martens","year":"2012","unstructured":"Martens HA, Nienhuis HL, Gross S, van der Steege G, Brouwer E, Berden JH, et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus. 2012;21:959\u201368.","journal-title":"Lupus"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1172\/JCI200114002","volume":"108","author":"AM Schmidt","year":"2001","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949\u201355.","journal-title":"J Clin Invest"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/hc0702.104183","volume":"105","author":"G Basta","year":"2002","unstructured":"Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816\u201322.","journal-title":"Circulation"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/bj20021371","volume":"370","author":"H Yonekura","year":"2003","unstructured":"Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097\u2013109.","journal-title":"Biochem J"},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716\u201327.","journal-title":"FASEB J"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"50019","DOI":"10.1074\/jbc.M409782200","volume":"279","author":"LE Hanford","year":"2004","unstructured":"Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004;279:50019\u201324.","journal-title":"J Biol Chem"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2174\/092986706777585013","volume":"13","author":"D Geroldi","year":"2006","unstructured":"Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971\u20138.","journal-title":"Curr Med Chem"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"R817","DOI":"10.1186\/ar1749","volume":"7","author":"R Pullerits","year":"2005","unstructured":"Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:R817\u201324.","journal-title":"Arthritis Res Ther"},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijcard.2010.05.075","volume":"145","author":"N Mahajan","year":"2010","unstructured":"Mahajan N, Dhawan V, Malik S, Jain S. Serum levels of soluble receptor for advanced glycation end products (sRAGE) in Takayasu\u2019s arteritis. Int J Cardiol. 2010;145:589\u201391.","journal-title":"Int J Cardiol"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-3083.2012.02691.x","volume":"75","author":"CY Ma","year":"2012","unstructured":"Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, Yang QR, et al. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol. 2012;75:614\u201322.","journal-title":"Scand J Immunol"},{"key":"569_CR22","first-page":"1139","volume":"14","author":"A Ohta","year":"1987","unstructured":"Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still\u2019s disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139\u201346.","journal-title":"J Rheumatol"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, S\u00e8ve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13:708\u201322.","journal-title":"Autoimmun Rev"},{"key":"569_CR24","first-page":"1","volume":"22","author":"S Kadavath","year":"2015","unstructured":"Kadavath S, Efthimiou P. Adult-onset Still\u2019s disease-pathogeensis, clinical manifestations, and new treatment options. Ann Med. 2015;22:1\u20139.","journal-title":"Ann Med"},{"key":"569_CR25","doi-asserted-by":"crossref","unstructured":"Narula N, Narula T, Abril A. Swizing the clinical presentation in adult onset Still\u2019s disease. An extensive literature review. Autoimmun Rev. 2015. [Epub ahead of print].","DOI":"10.1016\/j.autrev.2015.01.007"},{"key":"569_CR26","doi-asserted-by":"crossref","unstructured":"Ruscitti P, Cipriani P, Di Benedetto P, Ciccia F, Liakouli V, Carubbi F, et al. Increased level of H-ferritin and its imbalance with L-ferritin in bone marrow and liver of patients with adult onset Still\u2019s disease, developing macrophage activation syndrome, correlate with the severity of the diseases. Autoimmun Rev. 2015. [Epub ahead of print].","DOI":"10.1016\/j.autrev.2015.01.004"},{"key":"569_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","volume":"44","author":"M Kawashima","year":"2001","unstructured":"Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease. Arthritis Rheum. 2001;44:550\u201360.","journal-title":"Arthritis Rheum"},{"key":"569_CR28","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol. 2003;30:2422\u20137.","journal-title":"J Rheumatol"},{"key":"569_CR29","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol. 2004;31:2189\u201398.","journal-title":"J Rheumatol"},{"key":"569_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","volume":"140","author":"DL Kastner","year":"2010","unstructured":"Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784\u201390.","journal-title":"Cell"},{"key":"569_CR31","doi-asserted-by":"publisher","first-page":"480373","DOI":"10.1155\/2012\/480373","volume":"2012","author":"L Rossi-Semerano","year":"2012","unstructured":"Rossi-Semerano L, Kon\u00e9-Paut I. Is still\u2019s disease an autoinflammatory syndrome? Int J Inflam. 2012;2012:480373.","journal-title":"Int J Inflam"},{"key":"569_CR32","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19:424\u201330.","journal-title":"J Rheumatol"},{"key":"569_CR33","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3899\/jrheum.100247","volume":"37","author":"M Rau","year":"2010","unstructured":"Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis. J Rheumatol. 2010;37:2369\u201376.","journal-title":"J Rheumatol"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/art.1780300209","volume":"30","author":"JJ Cush","year":"1987","unstructured":"Cush JJ, Medsger TA, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still\u2019s disease: clinical course and outcome. Arthritis Rheum. 1987;30:186\u201394.","journal-title":"Arthritis Rheum"},{"key":"569_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still\u2019s disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"569_CR36","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"569_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombaridier","year":"1992","unstructured":"Bombaridier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The committee on prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630\u201340.","journal-title":"Arthritis Rheum"},{"key":"569_CR38","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/01.ASN.0000062961.76776.C1","volume":"14","author":"M Nangaku","year":"2003","unstructured":"Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14:1212\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"569_CR39","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1194\/jlr.M038968","volume":"54","author":"P Quade-Lyssy","year":"2013","unstructured":"Quade-Lyssy P, Kanarek AM, Baiersd\u00f6rfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res. 2013;54:3052\u201361.","journal-title":"J Lipid Res"},{"key":"569_CR40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1681\/ASN.V1191656","volume":"11","author":"N Tanji","year":"2000","unstructured":"Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"569_CR41","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3899\/jrheum.110058","volume":"38","author":"A Myles","year":"2011","unstructured":"Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation end products is decreased in patients with juvenile idopathic arthritis (ERA category) and inversely corelated with disease activity and S100A12 levels. J Rheumatol. 2011;38:1994\u20139.","journal-title":"J Rheumatol"},{"key":"569_CR42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","volume":"48","author":"H Maillard-Lefebvre","year":"2009","unstructured":"Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009;48:1190\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"569_CR43","doi-asserted-by":"publisher","first-page":"G823","DOI":"10.1152\/ajpgi.00115.2010","volume":"300","author":"J D\u00e4britz","year":"2011","unstructured":"D\u00e4britz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, L\u00fcgering A, et al. The functional -374\u00a0T\/A polymorphism of the receptor for advanced glycation end products may modulate Crohn\u2019s disease. Am J Gastroent Liver Physiol. 2011;300:G823\u201332.","journal-title":"Am J Gastroent Liver Physiol"},{"key":"569_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nm831","volume":"9","author":"SS Yan","year":"2003","unstructured":"Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9:287\u201393.","journal-title":"Nat Med"},{"key":"569_CR45","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/art.37955","volume":"65","author":"SW Lee","year":"2013","unstructured":"Lee SW, Park KH, Park S, Kim JH, Hong SY, Lee SK, et al. Soluble receptor for advanced glycation end products alleviates nephritis in (NZB\/NZW) F1 mice. Arthritis Rheum. 2013;65:1902\u201312.","journal-title":"Arthritis Rheum"},{"key":"569_CR46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/mol.52.1.54","volume":"52","author":"C Renard","year":"1997","unstructured":"Renard C, Chappey O, Wautier MP, Nagashima M, Morser J, Scherrmann JM, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 1997;52:54\u201362.","journal-title":"Mol Pharmacol"},{"key":"569_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1084\/jem.20030800","volume":"198","author":"T Chavakis","year":"2003","unstructured":"Chavakis T, Bierhaus A, AI-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507\u201315.","journal-title":"J Exp Med"},{"key":"569_CR48","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.nut.2011.11.005","volume":"28","author":"CN Roy","year":"2012","unstructured":"Roy CN, Semba RD, Sun K, Bandinelli S, Varadhan R, Patel KV, et al. Circulating selenium and carboxylmethyl-lysine, an advanced glycation end products, are independent predictors of anemia in older community-dwelling adults. Nutrition. 2012;28:762\u20136.","journal-title":"Nutrition"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-015-0569-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0569-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0569-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0569-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T14:54:41Z","timestamp":1651935281000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-015-0569-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s12891-015-0569-3","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,9]]},"assertion":[{"value":"23 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"111"}}